Neoton (Phosphocreatine Sodium)

Neoton acts on cardiac energy pathways to improve myocardial ATP availability during ischemic or surgical stress.

• Myocardial ischemia: helps restore ATP levels and may reduce ischemic injury.
• Cardiac surgery support: provides myocardial protection during operative periods.
• Heart failure: assists in augmenting cardiac energy reserves in chronic dysfunction.

• Phosphocreatine Sodium delivers exogenous phosphocreatine directly to the circulation. Once inside myocardial cells, phosphocreatine participates in the creatine kinase reaction, rapidly donating a phosphate group to ADP to regenerate ATP, thereby supporting cellular energy demand during periods of reduced oxygen supply or increased workload.

Adverse reactions may occur with intravenous administration of phosphocreatine sodium.

Common Side Effects

• Hypotension: transient drop in blood pressure during infusion.
• Flushing: mild redness of the skin.
• Nausea: occasional gastrointestinal discomfort.
• Headache: mild to moderate intensity.
• Local irritation: pain or erythema at the infusion site.

Serious or Rare Side Effects

• Arrhythmia: abnormal heart rhythm requiring monitoring.
• Anaphylactic reaction: severe allergic response with respiratory compromise.
• Hyperkalemia: elevated serum potassium levels.
• Metabolic acidosis: significant shift in acid‑base balance.
• Thrombophlebitis: inflammation of the vein with clot formation.

Neoton should be administered under close clinical supervision with appropriate monitoring.

• Cardiac monitoring: continuous ECG during and after infusion.
• Electrolyte assessment: check serum potassium and calcium before administration.
• Renal function: evaluate kidney function as phosphocreatine is renally cleared.
• Hemodynamic stability: ensure patient is hemodynamically stable prior to infusion.
• Contraindications: avoid in patients with known hypersensitivity to phosphocreatine.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before initiating therapy.

Major Interactions (Avoid)

• Concurrent high‑dose catecholamines: may exacerbate myocardial oxygen demand.
• ATP‑depleting agents (e.g., certain chemotherapy drugs): could counteract the intended benefit.

Moderate Interactions (Monitor Closely)

• Diuretics: monitor electrolyte balance, especially potassium.
• Beta‑blockers: observe for additive effects on heart rate and contractility.
• Anticoagulants: watch for changes in bleeding risk due to hemodynamic shifts.
• Other cardiac inotropes: adjust dosing based on combined hemodynamic impact.